Indaptus Therapeutics Inc

NASDAQ:INDP   3:59:51 PM EDT
2.33
-0.05 (-2.10%)
Regulatory, Earnings Announcements

Indaptus Therapeutics Reports First Quarter 2022 Financial Results

Published: 05/12/2022 12:35 GMT
Indaptus Therapeutics Inc (INDP) - Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update.
Q1 Loss per Share $0.41.
On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half of 2022.
Announces Submission of Investigational New Drug (ind) Application for Decoy20.
As of March 31, 2022, Company Had Cash, Cash Equivalents and Marketable Securities of Approximately $36.2 Million.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.46

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.50

More details on our Analysts Page.